Heparin-induced coagulopathy associated with staphylococcal protein a immunoadsorption treatment columns: An in vitro and in vivo analysis

Transfusion

Volumn 40, Issue 6, 2000, Pages 697-701

  Kunkel, J F ^a   Sarode, R ^a   Verba, M ^a   Yomtovian, Roslyn ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN;

ARTICLE; BLOOD CLOTTING DISORDER; CASE REPORT; CONTROLLED STUDY; HEPARINIZATION; HUMAN; IMMUNOADSORPTION; PARTIAL THROMBOPLASTIN TIME; RHEUMATOID ARTHRITIS; THROMBOCYTOPENIA;

ANTICOAGULANTS; ANTIGEN-ANTIBODY COMPLEX; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; CHROMATOGRAPHY, AFFINITY; HEMORRHAGIC DISORDERS; HEPARIN; HUMANS; IMMUNOGLOBULIN G; IMMUNOSORBENT TECHNIQUES; ISOANTIBODIES; PARTIAL THROMBOPLASTIN TIME; STAPHYLOCOCCAL PROTEIN A; THROMBOCYTOPENIA;

EID: 0034048422     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2000.40060697.x     Document Type: Article

References (14)

1. Snyder HW Jr, Balint JP Jr, Jones FP. Modulation of immunity in patients with autoimmune disease and cancer treated by extracorporeal immunoadsorption with PROSORBA® columns. Semin Hematol 1989;26(2 Suppl 1):31-41.
2. Balint JP Jr. Immune modulation associated with extracorporeal immunoadsorption treatments utilizing protein A/ silica columns. Artif Organs 1996:20:906-13.
3. Snyder HWJr, Cochran SK, Balint JP Jr, et al. Experience with protein A-immunoadsorption in treatment-resistant adult immune thrombocytopenic purpura. Blood 1992:79:2237-45.
4. Balint JP, Hussein MA, Quagliata F, et al. Modulation of idiotypic and antiidiotypic immunoglobulin G responses in an alloimmune thrombocytopenic patient associated with extracorporeal protein A immunoadsorption. Artif Organs 1996:20:266-70.
5. Muroi K, Sasaki R, Miura Y. The effect of immunoadsorption therapy by a protein A column on patients with thrombocytopenia. Semin Hematol 1989:26:10-4.
6. Wiesenhutter CW, Irish BL, Bertram JH. Treatment of patients with refractory rheumatoid arthritis with extracorporeal protein A immunoadsorption columns: a Pilot Trial. J Rheumatol 1994:21:804-12.
7. Felson DT, LaValley MP, Baldassare AB, et al. The PROSORBA column for the treatment of refractory rheumatoid arthritis: a randomized, double-blind, sham-controlled trial. Arthritis Rheum 1999:42:2153-9.
8. Kunkel JF, Verba MM, Eshleman S, et al. Double jeopardy: coagulopathy in thrombocytopenic patients undergoing staph protein A (SPA) immunoadsorption therapy (abstract). Transfusion 1997;37(Suppl):84S.
9. Tallarida RJ, Murray RB. Manual of pharmacologie calculations with computer programs. 2nd ed. New York: Springer-Verlag, 1987:77-81.
10. Hirsh J, Warkentin TE, Raschke R, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmokinetics, dosing, considerations, monitoring, efficacy, and safety. Chest 1998:114(5 Suppl):489S-510S.
11. Physicians' desk reference. 54th ed. Montvale, NJ: Medical Economics Company, 2000:3246.
12. Monreal M, Urrutia A, Marti S, et al. Platelet count and the risk of bleeding in hospitalized patients with venous thromboembolism starting anticoagulant therapy. Haemostasis 1997:27:91-8.
13. Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood 1991:78:2337-43.
14. Gmur J, Burger J, Schanz U, et al. Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia. Lancet 1991:338:1223-6.